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Human RFT1 Deficiency Leads
to a Disorder of N-Linked Glycosylation
Micha A. Haeuptle,1,5 Franc¸ois M. Pujol,2,5 Christine Neupert,3 Bryan Winchester,4
Alexander J. Kastaniotis,2 Markus Aebi,3 and Thierry Hennet1,*
N-linked glycosylation is an essential posttranslational modiﬁcation of proteins in eukaryotes. The substrate of N-linked glycosylation,
dolichol pyrophosphate (DolPP)-GlcNAc2Man9Glc3, is assembled through a complex series of ordered reactions requiring the transloca-
tion of the intermediate DolPP-GlcNAc2Man5 structure across the endoplasmic-reticulum membrane. A young patient diagnosed with
a congenital disorder of glycosylation characterized by an intracellular accumulation of DolPP-GlcNAc2Man5 was found to carry a homo-
zygous point mutation in the RFT1 gene. The c.199C/T mutation introduced the amino acid substitution p.R67C. The human RFT1
protein shares 22% identity with its yeast ortholog, which is involved in the translocation of DolPP-GlcNAc2Man5 from the cytosolic
into the lumenal side of the endoplasmic reticulum. Despite the low sequence similarity between the yeast and the human RFT1 pro-
teins, we demonstrated both their functional orthology and the pathologic effect of the human p.R67C mutation by complementation
assay in Drft1 yeast cells. The causality of the RFT1 p.R67C mutation was further established by restoration of normal glycosylation
proﬁles in patient-derived ﬁbroblasts after lentiviral expression of a normal RFT1 cDNA. The deﬁnition of the RFT1 defect establishes
the functional conservation of the DolPP-GlcNAc2Man5 translocation process in eukaryotes. RFT1 deﬁciency in both yeast and human
cells leads to the accumulation of incomplete DolPP-GlcNAc2Man5 and to a profound glycosylation disorder in humans.Introduction
N-linked glycosylation is a ubiquitous posttranslational mod-
iﬁcation of proteins in eukaryotes. N-glycans convey essential
signals for the folding and intracellular trafﬁckingof glycopro-
teins.1 N-glycans also inﬂuence the clearance of circulating
glycoproteins2 and the stability of signaling proteins at the
cell surface.3 A particular feature of N-glycans is that they
are ﬁrst assembled in the endoplasmic reticulum (ER) as
lipid-linked oligosaccharides (LLO). This assembly proceeds
through the sequential addition of monosaccharides to the
growing LLO. The process beginswith the addition ofGlcNAc
monophosphate to the lipid carrier dolicholphosphate (DolP)
and ends with the formation of DolPP-GlcNAc2Man9Glc3.
Theoligosaccharide is transferred to selected asparagine res-
idues of nascent glycoproteins.4 The assembly of LLO re-
quires glycosyltransferases and their respective nucleotide-
and dolichol-activated monosaccharide substrates, but it
also requires several proteins that regulate the complex to-
pology of the process. For example, the MPDU1 protein
makes the donor substrates DolP-Man and DolP-Glc avail-
able for completion of the LLO beyond DolPP-GlcNAc2-
Man5.
5–7 Similarly, it was previously shown that in yeast
the Rft1 protein is essential for translocation of the cytosoli-
cally oriented intermediate DolPP-GlcNAc2Man5 into the
ER lumen, where LLO assembly is completed.8
The pathway of LLO assembly is strongly conserved
among eukaryotes. Orthologous genes can be found from
yeasts to humans for all glycosyltransferases involved.
However, it is unclear whether the same degree of conser-vation applies to the accessory proteins. In fact, whereas
MPDU1 orthologs can be found in metazoan and plant
genomes, no orthologous gene can be identiﬁed in the
yeast genome. In the case of RFT1, only genes with limited
sequence similarity can be retrieved from the genome of
higher organisms, thus casting doubt upon the functional
signiﬁcance of RFT1 in the assembly of LLO in general.
The identiﬁcation of N-linked glycosylation disorders in
humans, often referred to as congenital disorders of glyco-
sylation (CDG), has demonstrated the conservation of the
LLO-assembly pathway between yeasts and humans.9 The
expression of human glycosyltransferase genes in glycosyl-
ation mutant yeasts demonstrated both the orthology of
the glycosyltransferases in question and the pathological
effect of the mutations identiﬁed in CDG cases.10–13
In spite of the extensive use of the yeast as a road map,
many cases of CDG have remained untyped. Clinically,
these cases present the symptoms typically seen inCDGpa-
tients, i.e., neurological abnormalities, failure to thrive, and
varying degrees of dysmorphism.7,14 In the present study,
we have identiﬁed a novel glycosylation defect in such an
untyped CDG case, thereby establishing the importance
of the RFT1 protein in human N-linked glycosylation.
Material and Methods
LLO and NLO Analysis
The investigation of the patient material was approved by the Eth-
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Figure 1. Lipid-Linked and N-Linked Oligosaccharide Profiles
The LLO isolated from healthy (A) and CDG (B) fibroblasts were separated by HPLC, demonstrating the abnormal accumulation of the LLO
DolPP-GlcNAc2Man5 in the CDG sample. The NLO isolated from healthy (C) and CDG (D) fibroblasts were identical, showing that complete
oligosaccharides were transferred to nascent proteins in the CDG cells. The retention times of DolPP-GlcNAc2Man1 (M1) to DolPP-
GlcNAc2Man9Glc3 (M9G3) derived from a yeast standard LLO are marked at the top of the profiles.conﬂuence. At that point, the ﬁbroblasts were rinsed in PBS and in-
cubated inGlc- and FCS-freeDMEMfor 45min, then labeled by ad-
dition of 150 mCi of [3H]-Man (54.0 Ci/mmol, Amersham Biosci-
ence) for 60 min. LLO and N-linked oligosaccharides (NLO) were
isolated fromlabeledﬁbroblasts by chloroform-methanol-water ex-
traction as described previously.13 Oligosaccharides were released
from LLO by mild acid hydrolysis and from NLO by N-glycosidase
F (New England BioLabs) digestion,13 then subjected to HPLC.15
Mutation Analysis
Total RNA and genomicDNAwere isolated from23 107 ﬁbroblasts
and 5 ml blood samples, respectively, with the TRIzol LS reagent
(Invitrogen) used according to the manufacturer’s instructions.
The human RFT1 cDNA was prepared from 2 mg of total RNA
with the primer 50-GGGCTTTTGGTCTTCACT-30 and 2 units of
Omniscript reverse transcriptase (QIAGEN). The 20 ml reaction
mixtures were incubated at 37C for 1 hr. The protein-coding
region of the human RFT1 cDNAwas ampliﬁed by PCR from 2 ml of
RT product with the primers 50-GGCGGCATTTCCTGGTGTCT-30
and 50-TGGCACTCTCTGGTGCCTCATC-30. The exon 3 of the
human RFT1 gene was ampliﬁed by PCR from 50 ng of genomic
DNAwith the primers 50-GGGCAATTCAGCTTTAGG-30 and 50-CAC
CACCAGTGGTTTATG-30. ThePCRproductswere sequenced (Syner-
gene Biotech, Switzerland) after removal of the unincorporated
nucleotides with QIAquick columns (QIAGEN). The presence of
the mutation was conﬁrmed by detection of the Pstl site, created
by the c.199C/T mutation in exon 3.
Plasmid Construction
For construction of the lentiviral expression vector, the human
RFT1 cDNA was subcloned as a PCR fragment ﬂanked by SpeI
and XhoI restriction sites into the NheI and SalI sites of the
pLenti6-EGFP plasmid (Invitrogen), thus yielding the pLenti6-
hRFT1 vector. The yeast rft1 gene with promoter and terminator
sequences was ampliﬁed from S. cerevisiae genomic DNA by
PCR and ligated into YCplac3316,17 with the inserted 50-PstI and
30-BamHI restriction sites to generate YCplac33-ScRFT1. The
pTSV30A-ScRFT116,17 plasmid was obtained by subcloning of
ScRFT1 from YCplac33-ScRFT1 with SacI and BamHI restrictionThesites. Plasmid YCplac33-pGAL1 was constructed by ampliﬁcation
of the GAL1 promoter from pYES2 (Invitrogen) and ligation of
the PCR product into YCplac33 with the inserted restriction sites
50-HindIII and 30-XbaI. The human RFT1 cDNA was obtained via
the EST clone IMAGE: 6422683 (Geneservice, UK). For construc-
tion of the plasmid YCplac33 pGAL1-hRFT1, the human RFT1
ORF was ampliﬁed from the IMAGE clone by PCR and cloned
into plasmid YCplac33 pGAL1 with the inserted restriction sites
50-XbaI and 30-SacI. The mutant RFT1[R67C] cDNA from the
CDG patient was subcloned into YCplac33 pGAL1 hRFT1, result-
ing in YCplac33-pGAL1-hRFT1[R67C].
Complementation of rft1D Yeast Mutants
Yeast strains W1536 5B (MATa, ade2D, ade3D, can1-100, his3-11,
15, leu2-3, 112, trp1-1, ura3-1) and W1536 8B (isogenic MATa
strain) have been described earlier.17 The diploid W1536a/a was
obtained by the mating of W1536 5B and W1536 8B. W1536
5B-rft1D was generated by introduction of the rft1::KanMX4
gene-replacement cassette into W1536a/a and selection for genet-
icin resistance followed by tetrad dissection on a SingerMSMman-
ual-dissection microscope (Singer Instrument). Haploid W1536
5B-rft1D mutant cells carry plasmid-borne rft1 in order to be via-
ble. The yeast cells were grown on either rich YPD (1% yeast ex-
tract, 2% peptone, and 2% D-Glc), YPGalD (1% yeast extract,
2% peptone, 2% D-Gal, and 0.05% D-Glc), YPR (1% yeast extract,
2% peptone, and 2% D-rafﬁnose), or synthetic complete media
(Sigma or QBiogene) lacking one or more nutrients. The colony-
sectoring method has been described by Bender et al.18 CPY im-
munoblotting was performed as described elsewhere.19
Lentiviral-Mediated RFT1 Expression
HEK293T cells (3 3 106) were transfected with 20 mg of pLenti6-
hRFT1 and 36 mg of the packing-plasmid mix (Invitrogen) via
calcium-phosphate precipitation. Eight hours after transfection,
the medium was replaced with fresh DMEM containing 10%
FCS. The cell supernatant was collected after 48 hr, and lentivi-
ruses were harvested by centrifugation at 3000 3 g for 5 min
and ﬁltration through 0.45 mmmembranes (Schleicher & Schuell,
Germany). CDG and healthy-control ﬁbroblasts were infectedAmerican Journal of Human Genetics 82, 600–606, March 2008 601
with recombinant lentiviral particles including the human RFT1
cDNA or the EGFP gene as controls. Infected cells were selected
with 5 mg/ml blasticidin (Invitrogen) for 10 days.
Results
A young girl was diagnosed with a disorder of N-linked
glycosylation on the basis of the detection of abnormal
isoelectric focusing of serum transferrin.20 The patient,
designated by the abbreviation KS,21 showed symptoms of-
ten encountered in CDG, namely, a marked developmen-
tal delay, hypotonia, seizures, hepatomegaly, and coagul-
opathy.21 Phosphomannomutase and phosphomannose
isomerase deﬁciencies were ruled out by the performance
of enzymatic testing (data not shown). To determine
whether the glycosylation disorder was related to a defect
of LLO assembly, we analyzed the LLO composition in
the healthy-control and patient ﬁbroblasts. The LLO pro-
ﬁle of control ﬁbroblasts was dominated by the full-length
DolPP-GlcNAc2Man9Glc3 (Figure 1A). By contrast, the pro-
ﬁle of the CDG patient was marked by an accumulation of
the intermediate LLO DolPP-GlcNAc2Man5 and a strong
reduction of complete LLO DolPP-GlcNAc2Man9Glc3
(Figure 1B). The analyses of NLO produced after 1 hr label-
ing of healthy-control and CDG ﬁbroblasts with [3H]Man
were indistinguishable. Both proﬁles showed peaks corre-
sponding to GlcNAc2Man8 andGlcNAc2Man9 oligosaccha-
rides (Figures 1C and 1D), which are normally found on
glycoproteins after the trimming of the N-linked glycans
by the ER glucosidases I and II and by the ER mannosidase.
The absence of GlcNAc2Man5 in the NLO proﬁle of the
CDGpatient suggested thatonly the full-lengthLLODolPP-
GlcNAc2Man9Glc3 was transferred to glycoproteins. This
phenotype was reminiscent of the LLO and NLO proﬁles
described in yeast depleted for the Rft1 protein.8 In condi-
tions with limiting RFT1 activity, DolPP-GlcNAc2Man5
accumulates at the cytosolic side of the ER membrane,
whereas the small amounts of ﬂipped oligosaccharide
are extended to DolPP-GlcNAc2Man9Glc3 and transferred
to proteins. This results in the underglycosylation of N-
glycoproteins.
The search for a human ortholog to the yeast Rft1
protein pointed to a single gene (GenBank, NM_052859)
that encodes a protein of 541 amino acids sharing 22%
identity with yeast Rft1. Sequencing of the NM_052859
cDNA in the CDG ﬁbroblasts revealed a C-to-T transition
at nucleotide position 199 (Figure 2A). This point muta-
tion led to the amino acid substitution p.R67C in the hu-
man RFT1 protein ortholog. Analysis of the NM_052859
gene in the DNA of the CDG patient’s parents conﬁrmed
the heterozygosity (Figure 2B). The c.199C/T mutation
was not seen in 210 control chromosomes of European or-
igin, thus excluding this mutation as a single-nucleotide
polymorphism. The p.R67C mutation was localized to
a 50-amino-acid-long hydrophilic stretch in the overall hy-
drophobic Rft1 protein ortholog (Figure 2C).602 The American Journal of Human Genetics 82, 600–606, MarchGenes encoding proteins with varying degrees of similar-
ity to the human RFT1 protein can be retrieved from all
eukaryote genomes analyzed, for which the sequence iden-
tity ranges from 87% for the mouse ortholog down to 17%
for fungal orthologs (Figure 3). Although the overall
protein sequence identity is limited, some regions of
RFT1 are strongly conserved across species. It is notewor-
thy that the region composing the p.R67C mutation was
strongly conserved and that several arginine residues,
including R67 in the human protein, were found in all
sequences analyzed (Figure 3), suggesting the importance
of these amino acids for proper functionality.
Growth of the yeast strain W1536-5B-rft1D relies on the
presence of the yeast rft1 gene on the plasmid pTSV30A-
ScRFT1. Cells of this strain background carrying this
Figure 2. Mutation Analysis of Human RFT1 in CDG
(A) Electropherograms of RFT1 cDNA surrounding nucleotide posi-
tion 199, marked by an arrow, sequenced from healthy-control and
patient cDNA.
(B) The same region was sequenced from the genomic DNA of the
CDG patient’s parents, showing the heterozygozity for the
c.199C/T mutation.
(C) The resulting p.R67C substitution, marked with a star, was pre-
dicted to be localized in a hydrophilic loop within the highly hy-
drophobic RFT1 protein. A potential N-glycosylation site detected
at position N227 is shown schematically.2008
Figure 3. RFT1 Protein-Sequence Comparison
Amino acid sequences of proteins derived from Homo sapiens, Mus musculus, Danio rerio, and Caenorhabditis elegans showing similarity to
the Saccharomyces cerevisiae RFT1 protein as performed by ClustalW analysis.30 Residues conserved in all five species are shown in black.
The R residue at position 67 in the human RFT1 protein (see arrow) is conserved in the five species. Total amino acid identity with the
human sequence ranged from 87% for the mouse protein down to 22% for the S. cerevisiae Rft1 protein.plasmid develop a red pigment, due to the presence of the
ADE3 gene onpTSV30A,whereas loss of this plasmid results
in white cells.18 Accordingly, W1536-5B-rft1D/pTSV30A-
ScRFT1 forms colonies that are uniformly red. This strain
was transformed with the additional plasmid YCplac33p-
GAL1-hRFT1 that leads to expression of the human RFT1
cDNA controlled by the galactose-inducible GAL1 pro-
moter. Such cells formed colonies that contain white sec-
tors, due to the fact that the pTSV30A-ScRFT1 plasmid was
no longer essential for growth and the plasmid could be
lost, as visualized by thewhite sectors (Figure 4A). This color
change indicated functional complementation of the rft1
defect by expression of the human RFT1 cDNA. This
experiment demonstrated that the investigated human
cDNA does indeed encode the orthologous protein to yeast
Rft1. The same experiment performed with a plasmid
expressing theCDGRFT1[R67C] allele didnot yield any sec-
toring colonies (Figure 4A), thus demonstrating that the
p.R67Cmutation led to reduced function even in the yeast
system. As shown previously,8 Rft1 depletion in yeast leads
to the underglycosylation of the vacuolar N-linked glyco-
protein carboxypeptidase Y. When W1536 5B-rft1D yeasts
were complemented with YCplac33 pGAL1-hRFT1, a nor-
mal carboxypeptidase Y glycosylation proﬁle was restored
(Figure 4B), thus showing that the effect of the human
RFT1 on rft1D yeast was indeed related to N-glycosylation.
Finally, we introduced a normal human RFT1 cDNA in
the ﬁbroblasts of the CDG patient to demonstrate thatThe Athe glycosylation disorder was the consequence solely of
the identiﬁed RFT1 mutation. Healthy-control and CDG
ﬁbroblasts were infected with recombinant lentiviruses
expressing either the normal RFT1 cDNA or EGFP as a
negative control. The analysis of LLO proﬁles in the
infected ﬁbroblasts showed an increased formation of the
full-length DolPP-GlcNAc2Man9Glc3 and a reduced pres-
ence of DolPP-GlcNAc2Man5 (Figure 5A), whereas the
EGFP expression control had no effect on the LLO proﬁle
(Figure 5B). The expression of either normal human RFT1
or EGFP in healthy control ﬁbroblasts had no effect on
the LLO proﬁles (data not shown).
Discussion
The identiﬁcation of a human glycosylation disorder asso-
ciated with an RFT1 defect underlines the functional
conservation of the RFT1 protein in eukaryotes. In spite
of a limited sequence similarity between the yeast and the
human RFT1 proteins, RFT1 deﬁciency led to identical bio-
chemical phenotypes in both species, i.e., to an accumula-
tion of the LLO DolPP-GlcNAc2Man5 and to a severe pro-
tein underglycosylation. Clinically, the RFT1-deﬁcientCDG
patient presented with symptoms frequently encountered
in CDG patients, namely, failure to thrive, psychomotor re-
tardation, seizures, hypotonia, and coagulopathy. Among
the various types of CDG, the clinical severity of the RFT1merican Journal of Human Genetics 82, 600–606, March 2008 603
deﬁciency resembled the diseases caused by ALG3 and
DPM1 deﬁciencies, also known as CDG-Id22 and
CDG-Ie,23,24 respectively. The ALG3 gene encodes the
DolP-Man-dependent mannosyltransferase that catalyzes
the elongation of LLO from DolPP-GlcNAc2Man5 to
DolPP-GlcNAc2Man6.
25 The DPM1 protein is the catalytic
subunit of the DolP-Man synthase complex.26 In CDG-Ie,
the shortage in DolP-Man impairs the elongation of the
LLO DolPP-GlcNAc2Man5 in the ER lumen. Although
DPM1, ALG3, andRFT1 defects all lead to the accumulation
of the LLO DolPP-GlcNAc2Man5, their impact on protein
N-glycosylation is expected to be different. In fact, an
RFT1 defect yields complete LLO structures for the transfer
toproteins, yet in limitedamount,whereasALG3andDPM1
defects yield low amounts of complete LLO combined with
the lumenal accumulation of the DolPP-GlcNAc2Man5. The
clinical similarities among these three glycosylation defects
suggest that the limited availability of complete LLO alone
dictates the extent of the clinical manifestations. In the
case of DPM1 deﬁciency, the decreased DolP-Man availabil-
ity is expected to also affect O-mannosylation and GPI-
anchor formation. Yet, the comparison between the clinical
features of DPM1 deﬁciency and those of ALG3 and RFT1
deﬁciencies suggests that the majority of the symptoms
are due to abnormal N-glycosylation.
Figure 4. Complementation of rft1D Yeasts
(A) W1536 5B rft1D/pTSV30A-ScRFT1 cells transformed with a plas-
mid carrying a complementing RFT1 variant will form sectored col-
onies as they are allowed to lose the red pigment-inducing pTSV30A
-ScRFT1 plasmid. Cells were transformed with: YCplac33 (mock),
YCp33 GAL ScRFT1, YCp33 GAL hRFT1[R67C], and YCp33 GAL hRFT1.
(B) Immunoblotting analysis of the yeast strain W1536 rftD trans-
formed with yeast and human RFT1 expressed from the yeast GAL1
promoter showed near wild-type levels of carboxypeptidase Y gly-
cosylation when grown on 2% Gal [G] and an accumulation of
underglycosylated isoforms when RFT1 expression was repressed
by 4% Glc [D]. Carbon source did not affect carboxypeptidase Y
glycosylation in wild-type yeast.604 The American Journal of Human Genetics 82, 600–606, MarchThe functional conservation of the yeast and human
RFT1 proteins emphasizes the essential role of RFT1 in
lower and higher eukaryotes. However, the function of
the RFT1 protein still remains unclear. The contribution of
RFT1 to the speciﬁc translocation of DolPP-GlcNAc2Man5
suggests that it may function as a ﬂippase,8 although such
an activity could not be conﬁrmed in vitro. A similar uncer-
tainty relates to the function of theMPDU1protein,5 which
is involved in making DolP-Man and DolP-Glc substrates
available toER lumenalmannosyl- andglucosyltransferases.
It is presently unclear whether MPDU1 affects the ﬂipping
of these substrates across the ER membrane or whether
MPDU1 affects their local concentration by a different
mechanism. It is noteworthy that a deﬁciency of MPDU1
inhumans leads toCDG,which is associatedwith the paral-
lel accumulation of LLO DolPP-GlcNAc2Man5 and DolPP-
GlcNAc2Man9.
6,7
To date, 21 forms of CDG have been divided into
13 types of CDG-I and eight types of CDG-II on the basis
of the nature of the glycosylation defects.27–29 In accor-
dance with the nomenclature guidelines established previ-
ously,27 we propose to name the RFT1 deﬁciency CDG-In.
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Figure 5. Lentiviral-Mediated Complementation in CDG Fibro-
blasts
The LLO profiles of fibroblasts infected with recombinant lentivi-
ruses expressing either human RFT1 (A) or EGFP as negative control
(B) were analyzed. The profiles show that the expression of the
normal RFT1 cDNA in CDG fibroblasts restored the synthesis of
the complete LLO DolPP-GlcNAc2Man9Glc3. The expression of EGFP
in CDG fibroblasts had no effect on the pathologic profile character-
ized by the accumulation of DolPP-GlcNAc2Man5. The retention
times of DolPP-GlcNAc2Man1 (M1) to DolPP-GlcNAc2Man9Glc3
(M9G3) are marked at the top of the profiles.2008
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